Rheumatic Heart Disease Overview
Rheumatic heart disease (RHD) is a chronic, progressive valvular heart disease caused by autoimmune damage following group A β-hemolytic streptococcal throat infection, remaining the most common cardiovascular disease in young people under 25 years globally and causing 233,000-468,000 deaths annually. 1
Pathophysiology and Disease Progression
RHD develops through a specific autoimmune cascade:
- Initial trigger: Group A β-hemolytic streptococcal pharyngitis (throat infection), with streptococcal skin infections also implicated 1
- Acute phase: Rheumatic fever develops as an autoimmune response to the streptococcal infection 2
- Chronic sequelae: After the initial rheumatic fever episode, 60-65% of patients develop valvular heart disease 1
- Progressive damage: Recurrent rheumatic fever episodes lead to cumulative valve damage, creating the chronic inflammatory state of RHD 1
The disease persists as chronic rheumatic valvulitis, with permanent valve tissue damage that often leads to heart failure 2.
Major Complications
As RHD progresses, patients develop life-threatening complications:
- Atrial fibrillation (affects up to one-third of RHD patients) 3
- Heart failure 1
- Stroke 1
- Infective endocarditis 1
- Pregnancy-related complications 1
Without access to cardiac surgery, patients die prematurely—mean age of death less than 25 years in some studies 1.
Global Burden and Epidemiology
The disease burden is staggering but often overlooked:
- 15.6-19.6 million existing cases globally (2005 conservative estimate) 1
- 282,000 new cases annually 1
- Emerging echocardiographic data suggest true prevalence may be several-fold higher than these estimates 1
- Virtually eliminated in high-income countries by the 1980s, but remains endemic in low- and middle-income countries 1
- Migration from endemic regions is causing re-emergence in high-income countries 1
In Australia specifically, First Nations peoples are affected at disproportionately high rates 4.
Prevention Framework
The WHO identifies four prevention levels for RHD 1:
Primordial Prevention
Improvement of environmental, social, and economic conditions in at-risk populations 1
Primary Prevention
Treatment of acute streptococcal pharyngitis with antibiotics to prevent initial rheumatic fever 1. Australian guidelines specifically recommend antibiotic treatment of skin and throat infections in high-risk individuals 4.
Secondary Prevention
Long-acting intramuscular benzathine penicillin G to prevent rheumatic fever recurrence in those with prior RF or RHD history 1. This limits disease progression and allows disease resolution 1. The injections are painful and require competent administration using pain-minimization strategies 4.
Tertiary Prevention
Medical and surgical treatment of RHD complications 1. Most affected patients present with severe valve disease, but limited access to life-saving cardiac surgery or percutaneous valve intervention contributes to increased mortality 5.
Clinical Management Challenges
The therapeutic difficulties stem from the need for prolonged medical treatment and lifelong surgical planning in a predominantly young population 6. Key challenges include:
- Gaps in understanding optimal medical and surgical treatment strategies persist 6
- Limited research investment because RHD has become uncommon in high-income countries where therapeutic innovations historically originate 6
- Most patients lack access to valve replacement procedures, which are currently the only treatment option for established RHD 7, 2
Critical Pitfalls
The key challenge in controlling RHD relates to identification and removal of barriers to translating existing knowledge into policy, programs, and practice 7. Despite advances in medical technology and disease understanding, RHD remains a serious public health problem because:
- Echocardiographic screening has improved diagnostic accuracy but highlighted the massive disease burden 5
- Preventing or providing early treatment for streptococcal infections is the most important step in reducing disease burden 5
- Strengthening health systems through integration with well-performing services is essential to ensure effective delivery of available therapies 6, 8
The World Heart Federation has set a strategic goal of 25% reduction in premature deaths from RF and RHD among individuals under 25 years by 2025 1, focusing on comprehensive register-based control programs, global access to benzathine penicillin G, RHD champions, training hubs, and vaccine development 1.